Mazyar Shadman, MD, MPH, joins the Oncology Brothers, Rohit Gosain, MD; and Rahul Gosain, MD, to discuss the SEQUOIA trial investigating zanubrutinib vs bendamustine-rituximab in first-line CLL/SLL.
Subgroup and Toxicity Analyses Favor Zanubrutinib Vs Ibrutinib in CLL
June 10th 2024During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed subgroup analyses and adverse events from the ALPINE trial of zanubrutinib for a patient with relapsed/refractory chronic lymphocytic leukemia in the second article of a 2-part series.
Read More